The global sickle cell disease treatment market size was valued at USD 3.51 billion in 2025 and is projected to grow from USD 3.97 billion in 2026 to USD 10.78 billion by 2034, registering a CAGR of 13.31% during the forecast period (2026–2034). North America dominated the sickle cell disease treatment market with a market share of 37.85% in 2025.
Sickle cell disease treatment includes medical therapies, gene therapies, and supportive care approaches used to manage symptoms, reduce complications, and improve quality of life for patients affected by sickle cell disorders. These treatments include medications, blood transfusions, stem cell therapies, and emerging gene-editing solutions.
The sickle cell disease treatment market demand is driven by the rising prevalence of sickle cell disorders, growing adoption of advanced therapies, and increasing focus on improving patient outcomes. Advances in gene therapy, increasing awareness, and expanding healthcare infrastructure are also contributing to sickle cell disease treatment market growth.
Download a Free Sample To learn more about this report,
The sickle cell disease treatment market is highly exposed to supply chain disruptions because it relies on globally sourced active pharmaceutical ingredients, biologics, gene therapy manufacturing capabilities, laboratory reagents, blood products, and specialized treatment systems requiring strict quality standards. Disruptions in these critical supplies can increase production timelines, delay patient access to essential therapies, and affect the consistent availability of disease management solutions worldwide. The market is expected to follow an S-shaped recovery, with gradual improvement as production capacity expands, supply networks stabilize, regulatory processes advance, and access to innovative sickle cell treatments increases.
Growing Adoption of Gene Editing Therapies for Long-term Disease Modification
The sickle cell disease treatment market is witnessing a shift toward gene editing approaches that aim to address the underlying genetic cause rather than only managing symptoms. Advanced therapies using technologies such as CRISPR are gaining attention as they offer potential long-term benefits for eligible patients. For example, CRISPR Therapeutics AG and its gene therapy approach with Casgevy represent the growing adoption of curative treatment strategies in the market.
Increasing Focus on Patient-centered Combination Treatment Approaches
Another major trend in the sickle cell disease treatment market is the increasing adoption of integrated treatment strategies that combine disease modifying medicines, transfusion support, and symptom management solutions. Healthcare providers are moving toward personalized care pathways to improve treatment outcomes and reduce complications associated with the disease. For example, hydroxyurea therapy combined with supportive care protocols is increasingly used to manage pain crises, anemia, and disease progression in sickle cell patients.
The sickle cell disease treatment market forecasts continued investment activity driven by the increasing adoption of gene therapies, rising demand for curative treatment approaches, and growing focus on advanced hematology solutions. Investors are focusing on companies developing gene-editing platforms, cell therapies, and innovative treatment technologies that improve long-term disease management, expand patient access, and address unmet medical needs in sickle cell disease.
In 2026, Beam Therapeutics entered a strategic financing agreement with Sixth Street valued at USD 500 million to support the advancement and potential commercialization of its sickle cell disease therapy risto-cel. The financing includes USD 100 million funded at closing along with additional milestone-based funding to strengthen clinical development, manufacturing capabilities, and future commercialization activities.
Expansion of Newborn Screening Programs and Increasing Investment in Gene Therapy Manufacturing Infrastructure Drives Market
The expansion of newborn screening programs is increasing demand for early-stage sickle cell disease treatments by enabling faster diagnosis and timely intervention. Early identification allows healthcare providers to initiate preventive therapies, vaccination programs, and disease-monitoring strategies before severe complications develop. For example, the US has expanded universal newborn screening for sickle cell disease, improving early access to treatments such as hydroxyurea and supportive care.
The growing investment in specialized gene therapy manufacturing infrastructure is improving the supply capacity of advanced sickle cell disease treatments. Gene-based therapies require complex cell processing facilities, advanced laboratory capabilities, and specialized production networks to support commercial availability. As production capabilities increase and treatment delivery networks mature, the availability of advanced therapies is expected to improve, supporting market growth and wider adoption of innovative treatment options.
High Cost of Advanced Gene Therapies and Shortage of Trained Healthcare Professionals Restrain Market Expansion
The high cost of gene based therapies, including complex manufacturing, specialized treatment centers, and long-term patient monitoring, increases the financial burden on healthcare systems and patients. For example, Casgevy, a gene-editing therapy approved for sickle cell disease, has a list price of approximately USD 2.2 million per treatment, while Lyfgenia is priced at approximately USD 3.1 million per treatment, creating significant affordability challenges. These therapies also require extensive infrastructure and reimbursement support, limiting availability in cost-sensitive markets. Thus, the high treatment cost of advanced sickle cell disease therapies remains a major restraint for wider market adoption.
The shortage of specialists experienced in gene therapy administration, hematology care, and advanced patient monitoring creates challenges in delivering complex sickle cell disease treatments. These therapies require coordinated care involving specialized clinical teams and dedicated treatment centers, which are limited in several regions.
Growing Adoption of AI-driven Patient Identification and Expansion of Sickle Cell Disease Treatment Access in Emerging Markets Offer Growth Opportunities to Market Players
The integration of artificial intelligence into rare disease diagnosis and patient identification is creating opportunities for healthcare technology companies and treatment developers. AI enabled platforms can identify eligible patients, predict disease progression, and optimize referral pathways for advanced therapies, improving treatment efficiency. Companies developing digital health platforms and clinical decision-support tools are expected to benefit from this trend.
The expansion of healthcare access programs in high prevalence regions creates growth opportunities for pharmaceutical manufacturers by increasing demand for affordable sickle cell disease treatments. Countries across Africa, the Middle East, and South Asia are strengthening screening, diagnosis, and treatment infrastructure to address rising patient needs. Companies developing cost-effective medicines, generic therapies, and scalable distribution models can benefit from these underserved markets.
Low Disease Awareness and Limited Availability of Compatible Donor Sources Challenges Market Growth
Limited awareness among patients and healthcare providers, along with inadequate diagnostic coverage in high-prevalence regions, restricts early identification and treatment initiation. Delayed diagnosis reduces demand for disease modifying therapies and limits market penetration in underserved populations.
The availability of matched blood and stem cell donors remains a challenge for patients requiring transfusion support or hematopoietic stem cell transplantation. Limited donor compatibility, particularly among diverse ethnic populations, reduces access to potentially curative transplant procedures and maintains dependence on long-term disease management therapies.
Request Customizationto receive a tailored report.
The blood transfusion segment accounted for a share of 41.28% revenue share in 2025, as chronic transfusion therapy remains the standard of care for stroke prevention and severe anemia in sickle cell disease. Its established clinical protocols, immediate therapeutic benefits, and widespread hospital availability continue supporting high treatment volumes globally.
The pharmacotherapy segment is expected to grow at a CAGR of around 14.33% during the forecast period due to increasing adoption of disease modifying drugs, expanding use of combination therapies, and improved patient adherence through convenient oral and infusion based treatment options. Broader regulatory approvals further accelerate segment growth.
By end user, hospitals accounted for a share of 59.30% in 2025 due to their ability to provide multidisciplinary hematology care, comprehensive transfusion services, and specialized infrastructure required for managing acute sickle cell complications and advanced therapies. These facilities also support intensive patient monitoring and emergency interventions.
The specialty clinics segment is expected to grow at a CAGR of 15.76% during the forecast period, driven by expanding dedicated hematology centers, increasing outpatient administration of disease-modifying therapies, and personalized long-term patient management programs. Their specialized expertise improves treatment continuity while reducing dependence on inpatient hospital services.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Early Adoption of Curative Therapies and Strong Rare Disease Treatment Infrastructure
The North America sickle cell disease treatment market accounted for the largest regional share of 37.85% in 2025, driven by early adoption of gene therapies, well-established rare disease treatment infrastructure, and favorable regulatory support for innovative therapies. The region benefits from a high concentration of comprehensive sickle cell treatment centers, advanced hematology networks, and strong reimbursement mechanisms for specialty treatments.
The US sickle cell disease treatment market was valued at USD 1.15 billion in 2025, driven by growing adoption of FDA-approved gene therapies, expanding newborn screening programs, and strong investment in rare disease research. According to the Centers for Disease Control and Prevention (CDC), sickle cell disease affects approximately 100,000 people in the US, supporting sustained demand for advanced treatment options.
The sickle cell disease treatment market in Canada was valued at USD 172.53 million in 2025, supported by expanding access to specialized hematology care, growing awareness of inherited blood disorders, and increasing government support for rare disease management. Healthcare systems are strengthening newborn screening initiatives, multidisciplinary care programs, and access to innovative therapies to improve long-term patient outcomes.
Asia Pacific: Fastest Growth Driven by Expanding Newborn Screening Programs and Increasing Access to Advanced Curative Therapies
The Asia Pacific sickle cell disease treatment market is expected to grow at a CAGR of 15.03% during the forecast period, showcasing the fastest regional growth. Growth is driven by expanding newborn screening initiatives, increasing access to advanced curative therapies, and rising investments in rare disease healthcare infrastructure. Governments and healthcare providers are strengthening genetic testing capabilities, establishing specialized hematology centers, and improving access to innovative treatments for inherited blood disorders.
The China sickle cell disease treatment market was valued at USD 189.87 million in 2025, supported by the expansion of genomic medicine programs and increasing integration of gene and cell therapy research into the country's biotechnology ecosystem. The country's growing biotechnology sector continues to create opportunities for advanced treatment adoption.
The India sickle cell disease treatment market was valued at USD 112.06 million in 2025, fueled by the implementation of the National Sickle Cell Anaemia Elimination Mission, the expansion of universal screening programs in tribal populations, and the increasing availability of dedicated hemoglobinopathy treatment centers. According to the World Health Organization, India accounts for one of the world's largest numbers of children born with sickle cell disease annually, highlighting the region's significant treatment demand.
The Japan sickle cell disease treatment market was valued at USD 97.12 million in 2025, supported by Japan’s leadership in regenerative medicine, advanced cell processing technologies, and translational research for gene-based therapies. Strong regulatory support for innovative regenerative medicines and investments in high-quality biopharmaceutical manufacturing infrastructure are accelerating the clinical development of advanced sickle cell disease treatments.
Unlock Regional Insightsto access country-level data, & regional trends.
The sickle cell disease treatment market competitive landscape is moderately consolidated, with competition concentrated among established pharmaceutical companies, biotechnology firms, and emerging gene therapy developers specializing in hematology and advanced therapeutics. Leading players compete through innovative treatment approaches, clinical development capabilities, regulatory approvals, and manufacturing expertise. Emerging companies focus on novel gene-editing platforms, targeted therapies, and personalized medicine solutions. The sickle cell disease treatment market ecosystem is shaped by advancements in gene therapy, increasing focus on curative treatments, and evolving regulatory pathways.
July 2026: US Food and Drug Administration approved the supplemental biologics license application (sBLA) for CASGEVY, making it the first gene therapy approved for children as young as two years with sickle cell disease, representing a major regulatory milestone for the market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com